A bottle of Coldrif cough syrup, which has been linked to the deaths of multiple children, Parasia, Madhya Pradesh. REUTERS/Priyanshu Singh/File Photo
One of the first special reports I read after joining Reuters was about children dying after taking cough syrup made in India. Almost three years later this continues.
Today we have an exclusive out, revealing that officials are investigating whether safety lapses in the supply of a pharmaceutical ingredient were responsible for contaminating cough syrup that has killed at least 24 children in recent months.
The fatalities, which began in September, have revived concerns about safety standards in India's $50 billion pharmaceutical sector, which was tarnished by the deaths of more than 140 children in Africa and Central Asia in 2022 and 2023 from Indian-made cough syrups made with contaminated solvents.
Reuters One Essential Read is sent three days a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.
Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.
This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.
